All stock lists
Unlock the score
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
4.03+0.01 (+0.25%)
Market cap
$8.09M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 1, 2016
Website
Insider Score
/ 100
QNRX Insider Score
Quoin Pharmaceuticals, Ltd. has a live Insider Score.
Scored on 4 qualifying trades from 4 insiders in the last 90 days.
Financial Health Score
Fair
From QNRX’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$18.8M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $3.8M
- Debt / equity
- 0.00
Liquidity17 / 20
Comfortably covers what is due within a year.
- Current assets
- $11.6M
- Current liabilities
- $6.6M
- Current ratio
- 1.76
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$15.4M
- Free cash flow
- -$15.4M
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 2.0M
- Share growth (1y)
- 11852.0%
- Cash runway
- 3 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
QNRX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 25.43 K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -25.43 K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 1.88 M | 1.70 M | 1.42 M | 1.74 M | 1.74 M | 1.58 M |
| R&D Expense | 3.66 M | 3.43 M | 3.10 M | 2.28 M | 2.05 M | 2.37 M |
| Operating Expenses | 5.54 M | 5.13 M | 4.52 M | 4.02 M | 3.79 M | 3.96 M |
| Operating Income | -5.57 M | -5.13 M | -4.52 M | -4.02 M | -3.79 M | -3.96 M |
| Pretax Income | -5.46 M | -5.00 M | -4.35 M | -3.95 M | -3.70 M | -3.81 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -5.46 M | -5.00 M | -4.35 M | -3.95 M | -3.70 M | -3.81 M |
| EPS (Basic) | -2.72 | -2.54 | -2.92 | -6.74 | -224.52 | -225.68 |
| EPS (Diluted) | -2.72 | -2.54 | -2.92 | -6.74 | -224.52 | -225.68 |
| Shares Outstanding | 2.01 M | 1.96 M | 1.50 M | 588.17 K | 16.80 K | 16.80 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.